Effect of Oat Compounds on Postprandial Glucose Response

Sponsor
Lund University (Other)
Overall Status
Completed
CT.gov ID
NCT05177172
Collaborator
(none)
20
1
5
1.6
12.4

Study Details

Study Description

Brief Summary

In this project we will investigate synergistic effects of oat polar lipids and beta glucans on postprandial glucose tolerance

Condition or Disease Intervention/Treatment Phase
  • Other: High beta glucans
  • Other: Low beta glucans
  • Other: Low beta glucans + low polar lipids
  • Other: Polar lipids
  • Other: Control
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
20 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Intervention Model Description:
Randomised food study in healthy subjectsRandomised food study in healthy subjects
Masking:
Single (Participant)
Masking Description:
Four test products and one reference product (control). Participants are not aware of which product that is served at each visits
Primary Purpose:
Prevention
Official Title:
Synergistic Effect of Oat Beta-glucans and Oat Polar Lipids on Postprandial Glucose Response
Actual Study Start Date :
Dec 1, 2021
Actual Primary Completion Date :
Jan 19, 2022
Actual Study Completion Date :
Jan 19, 2022

Arms and Interventions

Arm Intervention/Treatment
Placebo Comparator: Control

White wheat flour bread

Other: Control
No beta glucans or polar lipids

Experimental: High betaglucans

White wheat flour bread included beta glucans with the highest amounts in this study

Other: High beta glucans
higher dose betaglucans

Experimental: Low beta glucans

White wheat flour bread included beta glucans with the lowest amounts in this study

Other: Low beta glucans
lower dose beta glucans

Experimental: Low beta glucans + low polar lipids

White wheat flour bread included a combination of the lowest amounts of beta glucans and polar lipids

Other: Low beta glucans + low polar lipids
low dose betaglucans in a combination with low dose of polar lipids

Experimental: low polar lipids

White wheat flour bread included polar lipids

Other: Polar lipids
low dose polar lipids

Outcome Measures

Primary Outcome Measures

  1. Glucose tolerance [3 hours. Fasting (time =0 minutes), 15 minutes, 30 minutes, 45 minutes, 60 minutes, 90 minutes, 120 minutes, 150 minutes, 180 minutes]

    Postprandial glucose concentrations (mmol/L). The incremental area under the curve will be calculated and expressed as mmol*minutes/litre.

Secondary Outcome Measures

  1. Subjective appetite variables [3 hours. Fasting (time =0 minutes), 15 minutes, 30 minutes, 45 minutes, 60 minutes, 90 minutes, 120 minutes, 150 minutes, 180 minutes]

    Postprandial sensation of hunger, satiety, and desire to eat will be determined with a 100 millimeter visual analogue scale (VAS). The left end of the VAS scale represent "not at all" (e.g. hungry) and right end of the scale represented "extremely". One scale for each parameter will be used. The total area under the curve will be calculated, and the results will be expressed as millimeter*minutes.

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years to 40 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • healthy

  • BMI 20-28 kg/m2

  • Diet which follows the Nordic Nutrition Recommendations (non-vegetarian)

Exclusion Criteria:
  • fasting glucose > 6.1 mmol/L

  • metabolic diseases

  • gastrointestinal disease

  • chronic and/or psychological disease

  • food allergy

  • Vegetarian or vegan diets, or other special diets

Contacts and Locations

Locations

Site City State Country Postal Code
1 Lund University, Food Technology, Engineering and Nutrition Lund Sweden 22100

Sponsors and Collaborators

  • Lund University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Anne Nilsson, Associate professor, Lund University
ClinicalTrials.gov Identifier:
NCT05177172
Other Study ID Numbers:
  • Scanoats
First Posted:
Jan 4, 2022
Last Update Posted:
Jan 21, 2022
Last Verified:
Jan 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Anne Nilsson, Associate professor, Lund University

Study Results

No Results Posted as of Jan 21, 2022